

Assignment 04

Jovan Zivak

2025-10-26

```
# Standard set-up: libraries and data import  
library(caret)
```

```
## Loading required package: ggplot2
```

```
## Loading required package: lattice
```

```
library(tidyverse)
```

```
## -- Attaching core tidyverse packages ----- tidyverse 2.0.0 --  
## v dplyr      1.1.4      v readr      2.1.5  
## v forcats    1.0.1      v stringr   1.5.2  
## v lubridate  1.9.4      v tibble    3.3.0  
## v purrr      1.1.0      v tidyr     1.3.1
```

```
## -- Conflicts ----- tidyverse_conflicts() --  
## x dplyr::filter() masks stats::filter()  
## x dplyr::lag()     masks stats::lag()  
## x purrr::lift()    masks caret::lift()  
## i Use the conflicted package (<http://conflicted.r-lib.org/>) to force all conflicts to become errors
```

```
library(factoextra)
```

```
## Welcome! Want to learn more? See two factoextra-related books at https://goo.gl/ve3WBa
```

```
library(flexclust)
```

```
library(readxl)
```

```
Pharmaceuticals <- read_excel("C:/Users/jovan/Downloads/Pharmaceuticals.xlsx")  
#View(Pharmaceuticals)
```


```
PharmaClusterData <- Pharmaceuticals[, c(3:11)]
```

```
# Data normalization
```


```
PharmaScaled <- scale(PharmaClusterData)
```

```
# Cluster optimization via wss method
```

```
fviz_nbclust(PharmaScaled, kmeans, method = "wss")
```




```
# Cluster optimization via silhouette method for comparison  
fviz_nbclust(PharmaScaled, kmeans, method = "silhouette")
```



```
set.seed(123)
kmeans_result <- kmeans(PharmaScaled, centers = 5, nstart = 25)
fviz_cluster(kmeans_result, data = PharmaScaled)
```

Cluster plot



Responses and justification

#A) Z-score was used to normalize data due to the variation in value multiple orders of magnitude. After running both WSS and silhouette, 5 clusters were determined to be the optimal quantity. K-means itself was used because of the relative regularity of the data, falling into distinct clusters.

#B) The five-cluster solution reveals clear segmentation among the 21 pharmaceutical firms. Each polygon in the two-dimensional projection represents a financially distinct group. Cluster 4 (blue) contains closely related, low-risk firms with similar balance-sheet strength, while Cluster 2 (olive) stands out for its high-growth or high-profit profile. Cluster 3 (teal) is composed of a few small, specialized companies with distinctive financial ratios, and Cluster 1 (red) represents mid-performing firms with average profitability and size. Cluster 5 (purple) displays greater internal variability, suggesting firms with mixed strategies or transitional performance levels.

#C) Patterns were evident when comparing the clusters against qualitative firm characteristics. The most profitable and high-growth clusters (e.g., Cluster 2) tended to include firms with Buy or Strong Buy recommendations and were primarily listed on the NYSE, while smaller or lower-performing clusters had more diverse recommendations and exchange listings. This suggests that the financial performance-based clustering is consistent with analyst sentiment and firm size as reflected in exchange and

```
# location.
```

```
#D) Cluster 1: Average Performers  
# Cluster 2: Fast-Growing Companies  
# Cluster 3: Large, Stable Firms  
# Cluster 4: Highly-Borrowing Firms  
# Cluster 5: Smaller or Unpredictable Firms
```